<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02768155</url>
  </required_header>
  <id_info>
    <org_study_id>OFORT001</org_study_id>
    <nct_id>NCT02768155</nct_id>
  </id_info>
  <brief_title>Evaluation of Amniotic Fluid Product in Knee Osteoarthritis</brief_title>
  <official_title>Protocol for the Clinical Evaluation Amniotic Fluid (AF) Product in Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study evaluating Amniotic Fluid compared to a Saline Placebo Injection in the treatment of&#xD;
      subjects with osteoarthritic (OA) knee pain&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Pain</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kellgren-Lawrence grade of OA</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>AF 4.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amniotic Fluid 4.0ml dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AF 2.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amniotic Fluid 2.0ml dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Placebo Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Amniotic Fluid 4.0ml dose</intervention_name>
    <description>Injection of Amniotic Fluid</description>
    <arm_group_label>AF 4.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Amniotic Fluid 2.0ml dose</intervention_name>
    <description>Injection of Amniotic Fluid</description>
    <arm_group_label>AF 2.0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Control</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is 30 years or older.&#xD;
&#xD;
          2. Subject has a diagnosis of osteoarthritis (OA) defined as Grade 1 to 3 on the Kellgren&#xD;
             Lawrence grading scale.&#xD;
&#xD;
          3. Subject is willing and able provide informed consent and participate in all procedures&#xD;
             and follow-up evaluations necessary to complete the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has active infection at the injection site.&#xD;
&#xD;
          2. Subject has rheumatoid arthritis, psoriatic arthritis, or have been diagnosed with any&#xD;
             other auto-immune disorders that could be the cause of their knee pain.&#xD;
&#xD;
          3. BMI greater than 45 kg/m2&#xD;
&#xD;
          4. Subject has received an intra-articular hyaluronic acid (HA) injection for the&#xD;
             treatment of OA of the target knee within 3 months prior to screening.&#xD;
&#xD;
          5. Subject has received a steroid or platelet rich plasma (PRP) injection for the&#xD;
             treatment of OA of the target knee within 3 months prior to screening.&#xD;
&#xD;
          6. Subject has had major surgery, arthroplasty or arthroscopy in the target knee within&#xD;
             26 weeks of treatment or plans to have surgery in the target knee within 180 days of&#xD;
             treatment.&#xD;
&#xD;
          7. Subject is pregnant or plans to become pregnant within 180 days of treatment.&#xD;
&#xD;
          8. Subject has used an investigational drug, device or biologic within 12 weeks prior to&#xD;
             treatment.&#xD;
&#xD;
          9. Subject has any significant medical condition that, in the opinion of the&#xD;
             Investigator, would interfere with protocol evaluation and participation.&#xD;
&#xD;
         10. Subject has a history of immunosuppressive or chemotherapy in the last 5 years&#xD;
&#xD;
         11. Subject has autoimmune disease or a known history of having Acquired Immunodeficiency&#xD;
             Syndrome (AIDS) or HIV&#xD;
&#xD;
         12. Subject has had prior radiation at the site&#xD;
&#xD;
         13. Subject is currently taking anticoagulant therapy (excluding Plavix or Aspirin)&#xD;
&#xD;
         14. Diagnosis of gout in the past 6 month&#xD;
&#xD;
         15. Subject has a diagnosis of osteoarthritis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Fetterolf, MD</last_name>
    <role>Study Director</role>
    <affiliation>MiMedx Group, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Research Associates, Inc</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weil Foot, Ankle and Orthopedic Institute</name>
      <address>
        <city>Des Plaines</city>
        <state>Illinois</state>
        <zip>60016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OA, Osteoarthritis, Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

